$2.20
-0.09 (-3.93%)
Open$2.26
Previous Close$2.29
Day High$2.27
Day Low$2.05
52W High$5.08
52W Low$1.32
Volume—
Avg Volume788.9K
Market Cap145.87M
P/E Ratio—
EPS$-0.23
SectorBiotechnology
Analyst Ratings
Buy
14 analysts
Price Target
+1,893.2% upside
Current
$2.20
$2.20
Target
$43.85
$43.85
$27.62
$43.85 avg
$64.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 148.20M | 148.99M | 19.43M |
| Net Income | -73,969,724 | -66,927,467 | 4.04M |
| Profit Margin | -49.9% | -47.4% | 20.8% |
| EBITDA | -65,098,365 | -62,172,963 | 6.14M |
| Free Cash Flow | — | — | 2.37M |
| Rev Growth | -0.5% | -0.5% | +14.5% |
| Debt/Equity | 1.26 | 1.26 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |